Immunic, Inc.
NCM: IMUXLive Quote
About Immunic, Inc.
Healthcare
Biotechnology
Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical and phase 2 clinical development for patients with relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis. The company also develops IMU-856, which is entering Phase 2 clinical trial, for the restoration of the intestinal barrier function in patients suffering from gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, short bowel syndrome, irritable bowel syndrome with diarrhea, and other intestinal barrier function diseases; and IMU-381, which is in preclinical trial, for the treatment of gastrointestinal diseases. Immunic, Inc. was founded in 2016 and is headquartered in New York, New York.
📊 Fundamental Analysis
Immunic, Inc. demonstrates a profit margin of 0.0%, which is below the sector average, suggesting competitive pressure.
Return on Equity (ROE) is -1653.1%, which indicates that capital utilization is currently under pressure.
At a current price of $1.17, IMUX currently sits at the 66th percentile of its 52-week range (Range: $0.51 - $1.51).
🏥 Financial Health
🔴
Profit Margin
Weak
🔴
Return on Equity
Weak
🔴
Beta (Risk)
High Volatility
Key Financials
Market Cap
$167.00M
Trailing P/E
--
Forward P/E
-3.37
Beta (5Y)
1.37
52W High
$1.51
52W Low
$0.51
Avg Volume
3.55M
Day High
Day Low
📡 Subscribe to ZcoreAI updates
Join the list to get access to:
- Z-Score signals at market open
- New app features and updates
- Exclusive promo for ZcoreAI App